New incident report
Incident Report Number: 2023-4160
Registrant Reference Number: 2023-CA-000230
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: NEWFOUNDLAND
PMRA Registration No. 30735 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg
Yes
Unknown
Site: Animal / Usage sur un animal domestique
No
Animal's Owner
Cat / Chat
Domestic Mediumhair
1
Male
7
3.6
kg
Skin
>8 hrs <= 24 hrs / >8 h <= 24 h
<=30 min / <=30 min
System
>3 days <=1 wk / >3 jours <=1 sem
No
No
Fully Recovered / Complètement rétabli
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 21-Jun-2023, a 7 year old, approximately 3.6 kilogram, neutered, male, Domestic Mediumhair cat, in unknown condition, with no known concomitant medical conditions, was administered an unknown amount (but less than 0.25 tube) of Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg (Phenothrin (Sumithrin)) via the topical route by the animal owner. This was an extra label use due to the species. Immediately post application the cat developed scratching and licking. On 22-Jun-2023, the cat was bathed twice at the application site and slightly down its back with dish soap by the animal owner. On 23-Jun-2023, the cat developed anorexia. Bathing the cat fully with dish soap for product removal was recommended along with monitoring for persistent and worsening signs. On approximately 26-Jun-2023, the clinical signs resolved and the cat recovered. No further information is expected.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.